# Bering Capital

> Bering Capital is a VC fund in San Francisco backing Health Care and Biopharma. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 5
- Last investment: Jan 2024
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/beringcapital/
- Website: http://beringcapital.com

Bering Capital is a venture capital firm focused on biotech and medical technology.

## Contacts

5 contacts available for Bering Capital. Shizune tracks 3 team members at Bering Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bering-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 40% |
| Biopharma | 1 | 20% |
| Life Science | 1 | 20% |
| Therapeutics | 1 | 20% |
| Biotechnology | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 40% |
| Series D | 1 | 20% |
| Funding Round | 1 | 20% |
| Post-IPO Equity | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Evgeny Zaytsev | Co-Founder and Managing Partner | 16 | — |
| Evgeny Zaytsev | Co-Founder and Managing Partner | 1 | — |
| Philip Sawer | Managing Partner and Co-Founder | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $55M | Post-IPO Equity | Jan 22, 2024 |  |
| OncoResponse | OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer. | $14M |  | May 18, 2023 |  |
| OncoResponse | OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer. | $14M | Series D | May 18, 2023 |  |
| OncoResponse | OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer. | $40.6M | Series C | Mar 31, 2021 |  |
| CalciMedica | CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $15M | Series C | May 22, 2020 |  |

5 of 5 investments shown.

## Co-investors
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 3 deals together
- [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 3 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together
- [3B Future Health Fund](https://shizune.co/investors/profile/helsinn-investment-fund) — VC Fund, 2 deals together
- [Sanderling Ventures](https://shizune.co/investors/profile/sanderling-ventures) — VC Fund, 2 deals together
- [Takeda Ventures](https://shizune.co/investors/profile/takeda-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Bering Capital invest in?

Bering Capital invests primarily in Health Care, Biopharma and Life Science startups, most often at Series C and Series D stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Bering Capital?

Public channels for Bering Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Bering Capital?

The team at Bering Capital includes Evgeny Zaytsev (Co-Founder and Managing Partner), Evgeny Zaytsev (Co-Founder and Managing Partner) and Philip Sawer (Managing Partner and Co-Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co